Voyager Therapeutics Inc. (VYGR)
Company Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies.
The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease.
Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.
The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products.
Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Nov 11, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 172 |
| CEO | Dr. Alfred W. Sandrock Jr., M.D., Ph.D. |
Contact Details
Address: 75 Sidney Street Cambridge, Massachusetts United States | |
| Website | https://www.voyagertherapeutics.com |
Stock Details
| Ticker Symbol | VYGR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001640266 |
| CUSIP Number | 92915B106 |
| ISIN Number | US92915B1061 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alfred W. Sandrock Jr., M.D., Ph.D. | President, Chief Executive Officer & Director |
| Dr. Nathan D. Jorgensen M.B.A., Ph.D. | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer |
| Dr. Krystof Bankiewicz M.D., Ph.D. | Founder |
| Toby Ferguson M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Filing |
| Apr 23, 2025 | DEF 14A | Filing |
| Apr 04, 2025 | 4 | Filing |
| Apr 04, 2025 | 4 | Filing |
| Mar 11, 2025 | S-8 | Filing |
| Mar 11, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 4 | Filing |